ReviewFrontiers in oncology2025
Roles of E3 ubiquitin ligases and deubiquitinating enzymes in renal cell carcinoma.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fine-Tuning Protein Fate: Mechanisms of E1, E2, and E3 Enzymes and Deubiquitinases in Cell Signaling.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ubiquitination is an important post-translational modification of proteins that precisely regulates protein stability and function through the coordinated actions of E3 ubiquitin ligases (E3s) and deubiquitinases (DUBs), participating in biological processes including protein degradation and signal transduction. In recent years, the role of ubiquitination modification in the carcinogenesis, progression, and treatment of renal cell carcinoma (RCC) has garnered increasing attention. This review summarizes the structural classifications of key enzymes in the ubiquitination process-E3s and DUBs-and to discuss their specific molecular mechanisms in RCC. Finally, we discuss the targeted therapeutic strategies focusing on these key ubiquitination-modifying enzymes in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.